Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Haemonetics (HAE) EBIAT (2016 - 2025)

Haemonetics has reported EBIAT over the past 17 years, most recently at $44.7 million for Q4 2025.

  • For Q4 2025, EBIAT rose 19.33% year-over-year to $44.7 million; the TTM value through Dec 2025 reached $175.4 million, up 34.88%, while the annual FY2025 figure was $167.7 million, 42.64% up from the prior year.
  • EBIAT for Q4 2025 was $44.7 million at Haemonetics, up from $38.7 million in the prior quarter.
  • Over five years, EBIAT peaked at $58.0 million in Q1 2025 and troughed at -$11.0 million in Q2 2021.
  • A 5-year average of $27.5 million and a median of $32.1 million in 2022 define the central range for EBIAT.
  • Biggest five-year swings in EBIAT: tumbled 162.65% in 2021 and later skyrocketed 546.27% in 2022.
  • Year by year, EBIAT stood at $14.9 million in 2021, then surged by 121.76% to $32.9 million in 2022, then fell by 5.17% to $31.2 million in 2023, then rose by 20.02% to $37.5 million in 2024, then rose by 19.33% to $44.7 million in 2025.
  • Business Quant data shows EBIAT for HAE at $44.7 million in Q4 2025, $38.7 million in Q3 2025, and $34.0 million in Q2 2025.